{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:19:19Z","timestamp":1790727559733,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI094417"],"award-info":[{"award-number":["AI094417"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI054292"],"award-info":[{"award-number":["AI054292"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DE021291"],"award-info":[{"award-number":["DE021291"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI095113"],"award-info":[{"award-number":["AI095113"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI117802"],"award-info":[{"award-number":["AI117802"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI059457"],"award-info":[{"award-number":["AI059457"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["OD010850"],"award-info":[{"award-number":["OD010850"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["OD011092"],"award-info":[{"award-number":["OD011092"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM065794"],"award-info":[{"award-number":["GM065794"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201100013C"],"award-info":[{"award-number":["HHSN272201100013C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI100645"],"award-info":[{"award-number":["AI100645"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1108533"],"award-info":[{"award-number":["OPP1108533"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1133649"],"award-info":[{"award-number":["OPP1133649"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.coi.2017.06.010","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T13:30:23Z","timestamp":1500471023000},"page":"52-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination"],"prefix":"10.1016","volume":"47","author":[{"given":"Klaus","family":"Fr\u00fch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Picker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2017.06.010_bib0185","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/MMBR.00021-14","article-title":"Tuberculosis vaccines and prevention of infection","volume":"78","author":"Hawn","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.coi.2017.06.010_bib0190","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-med-042010-085643","article-title":"New paradigms for HIV\/AIDS vaccine development","volume":"63","author":"Picker","year":"2012","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.coi.2017.06.010_bib0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2016.05.011","article-title":"New concepts in HIV-1 vaccine development","volume":"41","author":"Stephenson","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2017.06.010_bib0200","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cell.2016.07.055","article-title":"Malaria: biology and disease","volume":"167","author":"Cowman","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.coi.2017.06.010_bib0205","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1097\/QAD.0000000000000788","article-title":"Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1","volume":"29","author":"Bui","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.coi.2017.06.010_bib0210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nm.3781","article-title":"B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers","volume":"21","author":"Fukazawa","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2017.06.010_bib0215","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ni.3158","article-title":"Antibody responses to envelope glycoproteins in HIV-1 infection","volume":"16","author":"Burton","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2017.06.010_bib0220","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/COH.0000000000000317","article-title":"Approaches to the induction of HIV broadly neutralizing antibodies","volume":"11","author":"Moore","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coi.2017.06.010_bib0225","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.4049\/jimmunol.1102695","article-title":"Hidden memories: frontline memory T cells and early pathogen interception","volume":"188","author":"Masopust","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2017.06.010_bib0230","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coi.2017.06.010_bib0235","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nm.1935","article-title":"Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge","volume":"15","author":"Hansen","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2017.06.010_sbref0240","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coi.2017.06.010_bib0245","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/imr.12428","article-title":"The comings and goings of MHC class I molecules herald a new dawn in cross-presentation","volume":"272","author":"Blander","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2017.06.010_sbref0250","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aac9475","article-title":"Broadly targeted CD8(+) T cell responses restricted by major histocompatibility complex E","volume":"351","author":"Hansen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coi.2017.06.010_sbref0255","doi-asserted-by":"crossref","first-page":"1237874","DOI":"10.1126\/science.1237874","article-title":"Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms","volume":"340","author":"Hansen","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coi.2017.06.010_bib0260","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.molimm.2012.10.022","article-title":"How to target MHC class II into the MIIC compartment","volume":"55","author":"Garstka","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.coi.2017.06.010_bib0265","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/eji.1830270517","article-title":"The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9","volume":"27","author":"Braud","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2017.06.010_bib0270","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.coi.2017.06.010_sbref0275","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.immuni.2016.09.015","article-title":"Antiviral CD8+ T cells restricted by human leukocyte antigen class II exist during natural HIV infection and exhibit clonal expansion","volume":"45","author":"Ranasinghe","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2017.06.010_bib0280","doi-asserted-by":"crossref","first-page":"2695396","DOI":"10.1155\/2016\/2695396","article-title":"Characteristics of HLA-E restricted t-cell responses and their role in infectious diseases","volume":"2016","author":"Joosten","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.coi.2017.06.010_sbref0285","doi-asserted-by":"crossref","first-page":"e1005421","DOI":"10.1371\/journal.ppat.1005421","article-title":"A conserved HIV-1-derived peptide presented by HLA-E renders infected T-cells highly susceptible to attack by NKG2A\/CD94-bearing natural killer cells","volume":"12","author":"Davis","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2017.06.010_bib0290","doi-asserted-by":"crossref","first-page":"10896","DOI":"10.1073\/pnas.1834449100","article-title":"HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes","volume":"100","author":"Pietra","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2017.06.010_bib0295","first-page":"63","article-title":"Cytomegalovirus cell tropism","volume":"325","author":"Sinzger","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.coi.2017.06.010_bib0300","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.virol.2013.08.026","article-title":"Coding potential of UL\/b\u2019 from the initial source of rhesus cytomegalovirus Strain 68-1","volume":"447","author":"Gill","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.coi.2017.06.010_bib0305","first-page":"37","article-title":"The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol","volume":"269","author":"van der Wal","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.coi.2017.06.010_bib0310","first-page":"333","article-title":"Cytomegalovirus immune evasion","volume":"325","author":"Powers","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.coi.2017.06.010_bib0315","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1128\/JVI.79.9.5786-5798.2005","article-title":"Rhesus cytomegalovirus contains functional homologues of US2, US3, US6, and US11","volume":"79","author":"Pande","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2017.06.010_bib0320","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1126\/science.1185350","article-title":"Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus","volume":"328","author":"Hansen","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.coi.2017.06.010_bib0325","doi-asserted-by":"crossref","first-page":"7730","DOI":"10.1128\/JVI.02696-09","article-title":"A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination","volume":"84","author":"Mohr","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2017.06.010_bib0330","doi-asserted-by":"crossref","first-page":"e1002295","DOI":"10.1371\/journal.ppat.1002295","article-title":"Sustained CD8+ T cell memory inflation after infection with a single-cycle cytomegalovirus","volume":"7","author":"Snyder","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2017.06.010_bib0335","doi-asserted-by":"crossref","first-page":"e9681","DOI":"10.1371\/journal.pone.0009681","article-title":"Cross-presentation of a spread-defective MCMV is sufficient to prime the majority of virus-specific CD8+ T cells","volume":"5","author":"Snyder","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2017.06.010_sbref0340","article-title":"Blocking virus replication during acute murine cytomegalovirus infection paradoxically prolongs antigen presentation and increases the CD8+ T cell response by preventing type I IFN-dependent depletion of dendritic cells","author":"Loo","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2017.06.010_bib0345","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.vaccine.2014.03.057","article-title":"Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease","volume":"32","author":"Fu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2017.06.010_sbref0350","doi-asserted-by":"crossref","first-page":"362ra145","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Wang","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2017.06.010_bib0355","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/503365","article-title":"A phase 1 study of 4 live, recombinant human cytomegalovirus Towne\/Toledo chimeric vaccines","volume":"193","author":"Heineman","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2017.06.010_sbref0360","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/infdis\/jiw365","article-title":"A phase 1 study of four live, recombinant human cytomegalovirus Towne\/Toledo chimera vaccines in CMV seronegative men","volume":"214","author":"Adler","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2017.06.010_sbref0365","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1084\/jem.20161988","article-title":"Fibroblast-adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans","volume":"214","author":"Murray","year":"2017","journal-title":"J Exp Med"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791517300237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791517300237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:34:27Z","timestamp":1760603667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791517300237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":37,"alternative-id":["S0952791517300237"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2017.06.010","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2017.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}